Evidence map›Paper›PMID 41516402›Full record

ArticleInternational journal of molecular sciences2026

Subtype-Specific m

Amal Qattan, Wafa Alkhayal, Kausar Suleman, Taher Al-Tweigeri, Asma Tulbah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amal QattanInnovation and Research Department, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.ORCID 0000-0001-7362-789X
Wafa AlkhayalSurgical Oncology Department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Kausar SulemanMedical Oncology Department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Taher Al-TweigeriMedical Oncology Department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.ORCID 0000-0002-6652-4419
Asma TulbahPathology and Laboratory Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer subtypes are known to have important pathobiological and clinical features. For example, triple-negative breast cancer (TNBC) remains one of the most aggressive and treatment-resistant breast cancer subtypes, lacking hormone and HER2 targets. Increasing evidence suggests that circular RNAs (circRNAs) and their N6-methyladenosine (m

Indexed as

AdenosineBiomarkers, TumorBreast NeoplasmsEpigenesis, GeneticRNA, CircularEpitranscriptomeEpitranscriptomicsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisRNA MethylationAdenosineBiomarkers, TumorN-methyladenosineRNA, CircularbiomarkercircRNAepitranscriptomicsm6A methylationmicroRNAnon-coding RNApost-transcriptional regulationprecision oncologytargeted therapytherapeutic targettriple-negative breast cancertumor progression

Identifiers

PMID41516402
PMCPMC12786885

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.